Fertility preservation for patients with melanoma.
Journal
Melanoma research
ISSN: 1473-5636
Titre abrégé: Melanoma Res
Pays: England
ID NLM: 9109623
Informations de publication
Date de publication:
01 10 2022
01 10 2022
Historique:
pubmed:
21
7
2022
medline:
9
9
2022
entrez:
20
7
2022
Statut:
ppublish
Résumé
The advent of immunotherapy and targeted therapy has outstandingly improved the prognosis in subjects with melanoma. Their use is now advocated also in earlier stages as an adjuvant therapy, and some neoadjuvant clinical trials are ongoing. Consequently, survivors free of disease are increasing, as well as those exposed to these new agents. Parenthood in survivors is, therefore, receiving growing interest. Evidence on the effects of immunotherapy and targeted therapy on future fertility is limited, but not entirely reassuring, in particular for immunotherapy. The necessity of delaying pregnancy seeking up to the end of treatments and follow-up (iatrogenic aging) is an additional albeit neglected source of concern, in particular for women in their late 30s. Subjects with melanoma should be informed on the multifaceted issue of future fertility at the time of cancer diagnosis. Available options of fertility preservations, including sperm and oocytes storage, should also be discussed, especially considering that at the age 0-39, melanoma represents the second most frequent neoplasia. In the decision-making process, most attention should be given to sex, age, and exposure to immunotherapy.
Identifiants
pubmed: 35855660
doi: 10.1097/CMR.0000000000000840
pii: 00008390-202210000-00001
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
303-308Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Curti BD, Faries MB. Recent advances in the treatment of melanoma. N Engl J Med. 2021; 384:2229–2240.
Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell. 2015; 160:1681–1696.
Seth R, Messersmith H, Kaur V, Kirkwood JM, Kudchadkar R, McQuade JL, et al. Systemic therapy for melanoma: ASCO guideline. J Clin Oncol. 2020; 38:3947–3970.
Grunewald S, Jank A. New systemic agents in dermatology with respect to fertility, pregnancy, and lactation. J Dtsch Dermatol Ges. 2015; 13:277–289; quiz 290.
Walter JR, Xu S, Paller AS, Choi JN, Woodruff TK. Oncofertility considerations in adolescents and young adults given a diagnosis of melanoma: fertility risk of food and drug administration-approved systemic therapies. J Am Acad Dermatol. 2016; 75:528–534.
Shirley M. Encorafenib and binimetinib: first global approvals. Drugs. 2018; 78:1277–1284.
Mehta A, Kim KB, Minor DR. Case report of a pregnancy during ipilimumab therapy. J Glob Oncol. 2018; 4:1–3.
Xu W, Moor RJ, Walpole ET, Atkinson VG. Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature. Melanoma Res. 2019; 29:333–337.
Cocorocchio E, Pala L, Battaglia A, Gandini S, Peccatori FA, Ferrucci PF. Fatherhood during dabrafenib and trametinib therapy for metastatic melanoma. Acta Oncol. 2018; 57:1131–1133.
Ghezzi M, Garolla A, Magagna S, Šabovich I, Berretta M, Foresta C, De Toni L. Fertility outcomes and sperm-DNA parameters in metastatic melanoma survivors receiving vemurafenib or dabrafenib therapy: case report. Front Oncol. 2020; 10:232.
Scovell JM, Benz K, Samarska I, Kohn TP, Hooper JE, Matoso A, Herati AS. Association of impaired spermatogenesis with the use of immune checkpoint inhibitors in patients with metastatic melanoma. JAMA Oncol. 2020; 6:1297–1299.
Rabinowitz MJ, Kohn TP, Peña VN, Samarska IV, Matoso A, Herati AS. Onset of azoospermia in man treated with ipilimumab/nivolumab for BRAF negative metastatic melanoma. Urol Case Rep. 2020; 34:101488.
Higham CE, Chatzimavridou-Grigoriadou V, Fitzgerald CT, Trainer PJ, Eggermont AMM, Lorigan P. Adjuvant immunotherapy: the sting in the tail. Eur J Cancer. 2020; 132:207–210.
de Filette J, Andreescu CE, Cools F, Bravenboer B, Velkeniers B. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm Metab Res. 2019; 51:145–156.
Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, et al. Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021; 9:e002435.
Sood A, Cole D, Abdollah F, Eilender B, Roumayah Z, Deebajah M, et al. Endocrine, sexual function, and infertility side effects of immune checkpoint inhibitor therapy for genitourinary cancers. Curr Urol Rep. 2018; 19:68.
Bosch E, Broer S, Griesinger G, Grynberg M, Humaidan P, Kolibianakis E, et al.; ESHRE Guideline Group on Ovarian Stimulation. Erratum: ESHRE guideline: ovarian stimulation for IVF/ICSI. Hum Reprod Open. 2020; 2020:hoaa067.
Boeri L, Capogrosso P, Salonia A. Gonadotropin treatment for the male hypogonadotropic hypogonadism. Curr Pharm Des. 2021; 27:2775–2783.
Silva CA, Cocuzza M, Carvalho JF, Bonfá E. Diagnosis and classification of autoimmune orchitis. Autoimmun Rev. 2014; 13:431–434.
Sharif K, Watad A, Bridgewood C, Kanduc D, Amital H, Shoenfeld Y. Insights into the autoimmune aspect of premature ovarian insufficiency. Best Pract Res Clin Endocrinol Metab. 2019; 33:101323.
Szeliga A, Calik-Ksepka A, Maciejewska-Jeske M, Grymowicz M, Smolarczyk K, Kostrzak A, et al. Autoimmune diseases in patients with premature ovarian insufficiency-our current state of knowledge. Int J Mol Sci. 2021; 22:2594.
Domniz N, Meirow D. Premature ovarian insufficiency and autoimmune diseases. Best Pract Res Clin Obstet Gynaecol. 2019; 60:42–55.
Hsieh YT, Ho JYP. Thyroid autoimmunity is associated with higher risk of premature ovarian insufficiency-a nationwide health insurance research database study. Hum Reprod. 2021;36:1621–1629.
Minhas S, Bettocchi C, Boeri L, Capogrosso P, Carvalho J, Cilesiz NC, et al. European association of urology guidelines on male sexual and reproductive health: 2021 update on male infertility. Eur Urol. 2021; 80:603–620.
Silva AF, Ramalho-Santos J, Amaral S. The impact of antisperm antibodies on human male reproductive function: an update. Reproduction. 2021: REP-21-0123.R1. [Epub ahead of print]
Nukumizu LA, Gonçalves Saad C, Ostensen M, Almeida BP, Cocuzza M, Gonçalves C, et al. Gonadal function in male patients with ankylosing spondylitis. Scand J Rheumatol. 2012; 41:476–481.
Rabelo-Júnior CN, Freire de Carvalho J, Lopes Gallinaro A, Bonfá E, Cocuzza M, Saito O, Silva CA. Primary antiphospholipid syndrome: morphofunctional penile abnormalities with normal sperm analysis. Lupus. 2012; 21:251–256.
Eijkemans MJ, van Poppel F, Habbema DF, Smith KR, Leridon H, te Velde ER. Too old to have children? Lessons from natural fertility populations. Hum Reprod. 2014; 29:1304–1312.
Mills M, Rindfuss RR, McDonald P, te Velde E; ESHRE Reproduction and Society Task Force. Why do people postpone parenthood? Reasons and social policy incentives. Hum Reprod Update. 2011; 17:848–860.
Salonia A, Matloob R, Saccà A, Ferrari M, Gallina A, Castiglione F, et al. Are Caucasian-European men delaying fatherhood? Results of a 7 year observational study of infertile couples with male factor infertility. Int J Androl. 2012; 35:125–132.
Khandwala YS, Zhang CA, Lu Y, Eisenberg ML. The age of fathers in the USA is rising: an analysis of 168 867 480 births from 1972 to 2015. Hum Reprod. 2017; 32:2110–2116.
Simard M, Laprise C, Girard SL. Impact of paternal age at conception on human health. Clin Chem. 2019; 65:146–152.
Halvaei I, Litzky J, Esfandiari N. Advanced paternal age: effects on sperm parameters, assisted reproduction outcomes and offspring health. Reprod Biol Endocrinol. 2020; 18:110.
Pohl E, Gromoll J, Wistuba J, Laurentino S. Healthy ageing and spermatogenesis. Reproduction. 2021; 161:R89–R101.
Johnson SL, Dunleavy J, Gemmell NJ, Nakagawa S. Consistent age-dependent declines in human semen quality: a systematic review and meta-analysis. Ageing Res Rev. 2015; 19:22–33.
Slama R, Bouyer J, Windham G, Fenster L, Werwatz A, Swan SH. Influence of paternal age on the risk of spontaneous abortion. Am J Epidemiol. 2005; 161:816–823.
Nybo Andersen AM, Urhoj SK. Is advanced paternal age a health risk for the offspring? Fertil Steril. 2017; 107:312–318.
Urhoj SK, Raaschou-Nielsen O, Hansen AV, Mortensen LH, Andersen PK, Nybo Andersen AM. Advanced paternal age and childhood cancer in offspring: a nationwide register-based cohort study. Int J Cancer. 2017; 140:2461–2472.
Islami F, Ward EM, Sung H, Cronin KA, Tangka FKL, Sherman RL, et al. Annual report to the nation on the status of cancer, part 1: National Cancer Statistics. J Natl Cancer Inst. 2021; 113:1648–1669.
Yousif R, Boull C, Gerami P, Nardone B, Vivar KL, Liszewski W. The demographics and trends in pediatric melanoma in the United States: an analysis of the National Cancer Database. Pediatr Dermatol. 2021; 38:1191–1197.
Tarasiewicz M, Martynowicz I, Knapp P, Sieczyński P. “Oncofertility” procedures in children and adolescents. Pediatr Endocrinol Diabetes Metab. 2019; 25:144–149.
Sofiyeva N, Siepmann T, Barlinn K, Seli E, Ata B. Gonadotropin-releasing hormone analogs for gonadal protection during gonadotoxic chemotherapy: a systematic review and meta-analysis. Reprod Sci. 2019; 26:939–953.
Ferrari S, Paffoni A, Filippi F, Busnelli A, Vegetti W, Somigliana E. Sperm cryopreservation and reproductive outcome in male cancer patients: a systematic review. Reprod Biomed Online. 2016; 33:29–38.
Schattman GL. Clinical practice. Cryopreservation of oocytes. N Engl J Med. 2015; 373:1755–1760.
Chambers GM, Adamson GD, Eijkemans MJ. Acceptable cost for the patient and society. Fertil Steril. 2013; 100:319–327.
ESHRE Capri Workshop Group. Economic aspects of infertility care: a challenge for researchers and clinicians. Hum Reprod. 2015; 30:2243–2248.
Cobo A, García-Velasco JA, Remohí J, Pellicer A. Oocyte vitrification for fertility preservation for both medical and nonmedical reasons. Fertil Steril. 2021; 115:1091–1101.
Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al.; CheckMate 238 Collaborators. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017; 377:1824–1835.
Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant Pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018; 378:1789–1801.
Eggermont AMM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. Eur J Cancer. 2019; 119:1–10.
Dummer R, Hauschild A, Santinami M, Atkinson V, Mandalà M, Kirkwood JM, et al. Five-year analysis of adjuvant Dabrafenib plus Trametinib in stage III melanoma. N Engl J Med. 2020; 383:1139–1148.
Zimmer L, Livingstone E, Hassel JC, Fluck M, Eigentler T, Loquai C, et al.; Dermatologic Cooperative Oncology Group. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020; 395:1558–1568.
Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS, et al. Fertility preservation in patients with cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018; 36:1994–2001.